Future Science Group
Browse
- No file added yet -

Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients - Supplementary Figure 1

Download (823.7 kB)
figure
posted on 2022-01-06, 10:53 authored by Jianbo Zhu, Guangpeng Chen, Kai Niu, Yongdong Feng, Lijiao Xie, Si Qin, Zhongyu Wang, Jixi Li, Song Lang, Wenlei Zhuo, Zhengtang Chen, Jianguo Sun

Supplementary Figure 1. Efficacy and safety of Rh-endostatin during peri-radiotherapy period in advanced non-small cell lung cancer patients

The outcomes of radiation pneumonitis (RP) in the Endostar group and the control group. The incidences of the RP remission, RP relapse and RP death were calculated based on the people who developed RP grade 2 and higher. The incidences of the pulmonary fibrosis were calculated based on the people who developed RP.

Funding

This study was supported by the National Key Research & Development Program (No. 2016YFC0106400), the National Natural Science Foundation of China (81773245, 81972858), the Technology Innovation and Application Development Project of Chongqing (cstccxljrc201910), and the Cultivation Program for Clinical Research Talents of Army Medical University (2018XLC1010).

History

Usage metrics

    Future Oncology

    Categories

    Keywords

    Recombinant human endostatin (Rh-endostatin)Non-small cell lung cancer (NSCLC)RadiotherapyPeri-radiotherapy periodRadiation TherapySolid TumoursCancer Therapy (excl. Chemotherapy and Radiation Therapy)

    Licence

    CC BY-NC-ND 4.0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC